Loading…
Galmed Pharmaceuticals Ltd. is projected to rise to $0.8506 by 2027, a +45% move from its current price of $0.585. GLMD is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean neutral.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.5578 | $0.5856 | $0.6148 | +0.10% |
| Aug 6 | $0.5473 | $0.5862 | $0.6279 | +0.21% |
| Aug 7 | $0.5394 | $0.5868 | $0.6384 | +0.31% |
| Aug 8 | $0.533 | $0.5874 | $0.6474 | +0.42% |
| Aug 9 | $0.5275 | $0.588 | $0.6556 | +0.52% |
| Aug 10 | $0.5226 | $0.5887 | $0.6631 | +0.62% |
| Aug 11 | $0.5182 | $0.5893 | $0.6701 | +0.73% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.5182 | $0.5893 | $0.6701 | +0.73% |
| Week 2 | $0.4949 | $0.5936 | $0.712 | +1.46% |
| Week 3 | $0.4785 | $0.5979 | $0.7471 | +2.20% |
| Week 4 | $0.4657 | $0.6022 | $0.7789 | +2.95% |
| Week 5 | $0.455 | $0.6066 | $0.8088 | +3.70% |
| Week 6 | $0.4459 | $0.6111 | $0.8373 | +4.46% |
| Week 7 | $0.438 | $0.6155 | $0.865 | +5.22% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Galmed Pharmaceuticals Ltd. is a biopharmaceutical company focused on developing therapeutics for liver diseases. It advances Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule, in a Phase III study for oral treatment of non-alcoholic steato-hepatitis (NASH) in overweight or obese patients with prediabetes or type II diabetes mellitus.
The ARRIVE Study, a Phase IIa trial, evaluates Aramchol in HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company also engages in Amilo-5MER development and MyBiotics pre-clinical work for NASH and fibrosis. It pursues partnerships and collaborations, including a license agreement with Samil Pharma Co., Ltd.
for Aramchol in Korea and a collaboration with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Galmed was founded in 2000 and is headquartered in Ramat Gan, Israel.
Galmed Pharmaceuticals Ltd. trades at $0.599 per share and has a market capitalization of $4.95M, ranking 5003 by market cap. The stock carries a near-term technical picture that is mixed-to-bullish, with a 30-day trading range of $0.4325 to $0.8296. Current price action sits near key technical levels, with a support at $0.505 and resistance at $0.648.
A major floor 23.4% below — a decisive break under it would weaken the trend.
The nearest floor, 13.7% below — buyers have tended to step in here.
The nearest ceiling, 10.8% above — a clean break opens room to run.
A major ceiling 34.2% above — clearing it would confirm fresh momentum.
Key GLMD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GLMD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.5682 | Buy | $0.5797 | Buy |
| MA 10 | $0.5446 | Buy | $0.5612 | Buy |
| MA 20 | $0.5465 | Buy | $0.5572 | Buy |
| MA 50 | $0.5852 | Sell | $0.5764 | Buy |
| MA 100 | $0.6015 | Sell | $0.6306 | Sell |
| MA 200 | $0.7639 | Sell | $0.8832 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 59.75 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 203.55 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 20.82 | Buy |
| Bollinger %B (20,2) | 1.12 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.36 | Sell |
| Awesome (5,34) | 0.00 | Buy |
| Ultimate (7,14,28) | 71.41 | Sell |
| Momentum (10) | 0.07 | Buy |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 0.60 | Sell |
| ADX (14) | 11.16 | Neutral |
| ATR (14) | 0.02 | Info |
The 30-day technical picture shows bullish sentiment, with RSI14 at 60 and price action around the short-term moving average. The stock trades above the SMA50, which sits at $0.5843, while the SMA200 stands at $0.7681, indicating a closer-to-mid-term uptrend but longer-term resistance above. The 30-day range spans from $0.4325 to $0.8296, illustrating a defined but sizable trading band around the current level of $0.599.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.469 | $0.585 | $0.8295 | 0% | Neutral | |
| $0.6306 | $0.8506 | $1.24 | +45% | Bullish | |
| $0.5605 | $0.7987 | $1.23 | +37% | Bullish | |
| $0.5492 | $0.8199 | $1.33 | +40% | Bullish | |
| $0.5293 | $0.8239 | $1.38 | +41% | Bullish | |
| $0.4671 | $0.7559 | $1.31 | +29% | Bullish | |
| $0.5501 | $0.9236 | $1.65 | +58% | Bullish | |
| $0.6769 | $1.18 | $2.16 | +101% | Bullish | |
| $0.7153 | $1.29 | $2.42 | +120% | Bullish | |
| $0.6426 | $1.20 | $2.30 | +104% | Bullish | |
| $0.8307 | $1.81 | $3.81 | +210% | Bullish | |
| $1.31 | $2.91 | $6.70 | +398% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.469 | $0.585 | $0.6925 | +0.00% |
| September 2026 | $0.489 | $0.5914 | $0.7443 | +1.09% |
| October 2026 | $0.5251 | $0.6431 | $0.8245 | +8.74% |
| November 2026 | $0.517 | $0.6396 | $0.8323 | -0.53% |
| December 2026 | $0.5037 | $0.6291 | $0.8295 | -1.65% |
Click any year to see its month-by-month GLMD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Galmed Pharmaceuticals Ltd.'s 2026 outlook centres on $0.585, within a $0.469 to $0.8295 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, GLMD could reach as high as $1.24, with a base case around $0.8506 and support toward $0.6306 — roughly +45% from $0.585. Momentum favours further upside here.
Expect GLMD to range from $0.5605 to $1.23 through 2028. The $0.7987 average target implies a +37% move from current prices. That is -6% versus the projected 2027 average. Buyers look set to stay in control over this stretch.
The GLMD price prediction for 2029 points to an average of $0.8199 (low $0.5492, high $1.33) — a potential gain of +40% on today's $0.585. Momentum favours further upside here.
In 2030, GLMD is projected to trade between $0.5293 and $1.38, averaging $0.8239 — a potential gain of +41% from today's $0.585. That is up 0% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Galmed Pharmaceuticals Ltd.'s 2031 outlook centres on $0.7559, within a $0.4671 to $1.31 range. That is -8% versus the projected 2030 average. That marks a +29% change versus current levels. Momentum favours further upside here.
By 2032, GLMD could reach as high as $1.65, with a base case around $0.9236 and support toward $0.5501 — roughly +58% from $0.585. Buyers look set to stay in control over this stretch.
Expect GLMD to range from $0.6769 to $2.16 through 2033. The $1.18 average target implies a +101% move from current prices. That is up +27% on the projected 2032 average. Momentum favours further upside here.
The GLMD price prediction for 2034 points to an average of $1.29 (low $0.7153, high $2.42) — a potential gain of +120% on today's $0.585. Buyers look set to stay in control over this stretch.
In 2035, GLMD is projected to trade between $0.6426 and $2.30, averaging $1.20 — a potential gain of +104% from today's $0.585. That is -7% versus the projected 2034 average. Momentum favours further upside here.
Galmed Pharmaceuticals Ltd.'s 2040 outlook centres on $1.81, within a $0.8307 to $3.81 range. That is up +52% on the projected 2035 average. That marks a +210% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, GLMD could reach as high as $6.70, with a base case around $2.91 and support toward $1.31 — roughly +398% from $0.585. Momentum favours further upside here.
Investing $1,000 in GLMD today (≈ 1,709.401709 GLMD) could be worth
$4,978.79
+$3,978.79 (+398%) by 2050 · US Dollar
Based on the average projected GLMD price of $2.91 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GLMDwould be worth at today's price.
$1,000 invested in GLMD on Jul 31, 2025 (≈ 613.496934 GLMD) would be worth
$358.9
-$641.1 (-64.1%) today · 0.36× · US Dollar
Based on a GLMD entry price of $1.63 vs. today's $0.585.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.513 | $1,140.35 | +14.0% |
| 1 month ago | $0.648 | $902.78 | -9.7% |
| 3 months ago | $0.571 | $1,024.52 | +2.5% |
| 6 months ago | $0.665 | $879.7 | -12.0% |
| 1 year ago | $1.63 | $358.9 | -64.1% |
| All time (5.0y) ago | $514.8 | $1.14 | -99.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GLMD forecast.
Our base-case forecast reaches $1.20 around 2034.
Implied market cap at $1.20: $9.92M
The multi-year forecast paints a generally bullish path, with the average price rising across several years and notable upside in later periods. For 2026, the average is $0.599 with a flat ROI of 0%, and by 2027 the average climbs to $0.8732 with a 45.8% ROI. Subsequent years show continued upside, including 2030 with an average of $0.8383 and a 39.9% ROI, 2040 at $1.77 with a 194.9% ROI, and 2050 at $2.80 with a 367.7% ROI.
Sentiment remains BULLISH across most forecast years. Long-horizon risk factors include high volatility, as indicated by an annualized volatility of 90%.
Tap a question to reveal the answer.
2030 forecast shows min $0.5351, avg $0.8383, max $1.42 with a 39.9% ROI and sentiment BULLISH.
The forecast includes several bullish years with positive ROI (e.g., 2027 45.8%, 2028 35%, 2029 39.6%, 2030 39.9%, 2032 52.7%, 2033 96.7%, 2034 112.2%, 2035 98.4%, 2040 194.9%, 2050 367.7%), but 2026 shows 0% ROI. These figures are estimates and not guarantees, and the stock carries high volatility (90%).
The 2035 forecast lists a max of $2.30, with an average of $1.19 and a min of $0.6322, indicating potential for $2.00 or higher within the forecast window.
Current price is $0.599 and market capitalization is $4.95M.
The stock shows bullish sentiment with RSI 60. It trades around the SMA50 of $0.5843 and below the SMA200 of $0.7681. The 30-day range is $0.4325 to $0.8296, with support at $0.505 and resistance at $0.648, and volatility around 90%.
Galmed Pharmaceuticals Ltd. Community Discussion
0Share your Galmed Pharmaceuticals Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.